Glycomine, Inc

Glycomine has spent more than a decade investigating the treatment of glycosylation disorders, starting with phosphomannomutase-2 congenital disorder of glycosylation (PMM2-CDG). And now with $115m in

Venture capital investors have not taken the summer off, at least not during the first few weeks of June, continuing to support mega-rounds of $100m or more for biopharmaceutical companies with novel

Achilles Raises £100m In Series B Round Cancer immunotherapy company Achilles Therapeutics Ltd. raised £100m ($121m) in its Series B round. RA Capital led and was joined by founding investor Syncona

Landos Biopharma Inc. announced a $60m series B venture capital financing on 13 August to keep the development plan for its rapidly progressing oral drug candidate BT-11 for inflammatory bowel diseas